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Abstract The role of cardiac troponins as diagnostic
biomarkers of myocardial injury in the context of acute
coronary syndrome (ACS) is well established. Since the
initial 1st-generation assays, 5th-generation high-sensitiv-
ity cardiac troponin (hs-cTn) assays have been developed,
and are now widely used. However, its clinical adoption
preceded guidelines and even best practice evidence. This
review summarizes the history of cardiac biomarkers with
particular emphasis on hs-cTn. We aim to provide insights
into using hs-cTn as a quantitative marker of cardiomy-
ocyte injury to help in the differential diagnosis of coronary
versus non-coronary cardiac diseases. We also review the
recent evidence and guidelines of using hs-cTn in sus-
pected ACS.
Keywords Cardiac biomarkers  High-sensitivity cardiac
troponin  Acute coronary syndrome
Introduction
A rapid and accurate diagnosis is critical in patients with
presumed acute coronary syndrome for the initiation of
effective evidence-based medical management and revas-
cularization. The third universal definition of myocardial
infarction defines an acute myocardial infarction (AMI) as
evidence of myocardial necrosis in a patient with the
clinical features of acute myocardial ischemia, and defines
the 99th percentile of cardiac troponins as the decision
value for AMI [1]. Clinical assessment, 12-lead ECG and
cardiac troponin (cTn) I or T form the diagnostic corner-
stones of patients with acute onset chest pain. Contempo-
rary sensitive and high-sensitivity cardiac troponin (hs-
cTn) assays have increased diagnostic accuracy in patients
with acute chest pain in comparison with conventional
cardiac biomarkers [2]. Rapid rule-in and rule-out diag-
nostic strategies for patients with chest pain in the emer-
gency department (ED) are now available, and help
clinicians to risk stratify patients and enable discharge of
those deemed to be at very low risk. In principle, this
improves assessment and makes ED care more cost
effective. However, there is potential for confusion, misuse
and unnecessary follow-up examinations when they are
used imprudently [3]. Novel hs-cTn assays are able to
quantify troponin in the majority of healthy individuals [4].
Although hs-cTn assays are very sensitive, they are less
specific for AMI when using the 99th percentile as a single
cutoff level [5]. Even when a troponin rise is consistent
with a diagnosis of AMI, other cardiac diseases such as
myocarditis, Tako-tsubo cardiomyopathy or shock can
produce significant changes of troponin as well. Interpre-
tation of the results is heavily dependent on the clinical
context in which it is requested.
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The aim of the current article is to review the history and
evolution of cardiac biomarkers of acute coronary syn-
drome, define what troponin is, and aid in the use of the hs-
cTn in clinical practice according to current guidelines.
History of cardiac biomarkers
Aspartate Transaminase (AST) became the first biomarker
used in the diagnosis of AMI [6] (Fig. 1). AST was widely
used in the 1960s and was incorporated into the World
Health Organization (WHO) definition of AMI [7]. How-
ever, AST is not specific for cardiac muscle, and its
detection is, therefore, not specific for cardiac damage. By
1970s, two further cardiac biomarkers were in use: lactate
dehydrogenase (LDH) and creatine kinase (CK). Although
neither is absolutely specific for cardiac muscle, CK is
more specific than LDH in the context of AMI, especially
in patients having other co-morbidities such as muscle or
hepatic disease [8]. Myoglobin is a small globular oxygen-
carrying protein found in heart and striated skeletal muscle
[9]. The first method to detect myoglobin in the serum was
developed in 1978. Myoglobin rises after acute myocardial
injury, and it became a useful cardiac biomarker in the
differential diagnosis of suspected AMI [10]. In the era of
hs-cTn, testing of myoglobin as an early marker of
myocardial necrosis is no longer recommended, neither as
a single marker nor in a multi-marker strategy [11, 12].
Eventually, advancements in electrophoresis allowed the
detection of cardiac-specific iso-enzymes of CK and LDH,
i.e., CK-MB and LDH 1 ? 2 [13]. Cardiac muscle has
higher CK-MB levels (25–30%) compared to skeletal
muscle (1%), which is mostly composed of CK-MM. These
assays played an important role in the diagnosis of AMI for
two decades, and were included as one of the diagnostic
criteria to rule out AMI by the WHO in 1979 [14]. How-
ever, the lack of specificity and the high rate of false-
positive results limited their usefulness. A more cardiac-
specific biomarker was needed.
In 1965, a new protein constituent of the cardiac
myofibrillar apparatus was discovered, which subsequently
came to be known as troponin [15]. In the late 1990s, a
sensitive and reliable radioimmunoassay was developed to
detect serum troponin [16]. Numerous studies demonstrate
that troponins appear in the serum 4–10 h after the onset of
AMI [17]. Troponin levels peak at 12–48 h, but remain
elevated for 4–10 days. The sensitivity for detecting tro-
ponin T and I approaches 100% when sampled 6–12 h after
acute chest pain onset [18]. Therefore, in the context of
acute chest pain, to reliably rule out AMI, patients need to
have a repeat troponin sample 6–12 h after the initial
assessment. Consequently, patients were increasingly
admitted to observational chest pain units.
What is troponin?
Troponin is a component of the contractile apparatus
within skeletal and cardiac myocytes. Along with calcium
ions, troponin proteins regulate and facilitate the interac-
tion between actin and myosin filaments as part of the
sliding filament mechanism of muscle contraction. Cardiac
troponin (cTn) is a complex comprising three subunits:
• troponin T attaches the troponin complex to the actin
filament;
• troponin C acts as the calcium binding site;
• troponin I inhibits interaction with myosin heads in the
absence of sufficient calcium ions.
Troponin C is synthesised in skeletal and cardiac mus-
cle. Troponin T and I isoforms are highly specific and
sensitive to cardiac myocytes and, therefore, are known as
cardiac troponins (cTn). The detection of cTn-T or cTn-I in
the blood stream is, therefore, a highly specific marker for
cardiac damage [19]. 92–95% of troponin is attached to the
actin thin filaments in the cardiac sarcomere, and the
remaining 5–8% is free in the myocyte cytoplasm [20].
Free, unbound cTn constitutes the ‘early releasable
Fig. 1 Timeline of the
development of cardiac
biomarkers for the diagnosis of
acute myocardial infarction
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troponin pool’ (ERTP) [4]. The concept of the ERTP helps
when considering the various mechanisms of troponin
release into the blood stream. ERTP is thought to be
released immediately following myocyte injury and,
assuming normal renal function, this would be cleared
promptly. This is contrary to the structurally bound cTn,
which degrades over a period of several days causing a
more stable and gradual troponin release.
The plasma half-life of cTn is around 2 h. Although the
precise mechanism by which troponin is eliminated from
the body remains unclear, it is hypothesized that troponin is
cleared, at least in part, by the renal reticulo-endothelial
system [21].
High-sensitivity cardiac troponin
Most hospitals now have replaced conventional cTn tests with
the new 5th generation hs-cTn T and I assayswhich can detect
troponin at concentrations 10- to 100-fold lower than con-
ventional assays (Fig. 2). Various terms for ‘‘more sensitive’’
cTn assays have been proposed for marketing purposes.
Troponin assays are recommended to be differentiated in
conventional, sensitive and high-sensitivity cTn assays.
Basically, hs-cTn assays detect troponin with higher sensi-
tivity and precision at an earlier point of time [22], and allow
detection and quantification in 50% to ideally 95% of healthy
individuals (Table 1) [23].Troponins are quantitativemarkers
of cardiomyocyte injury, and the likelihood of AMI increases
with increase in the level of cTn [24]. The negative predictive
value (NPV) of hs-cTn assays is[95% for AMI exclusion
when patients are tested on arrival at the ED [25]. If this is
repeated at 3 h, this rises to nearly 100% [26]. Shah et al.
demonstrated that using lower cutoffs for hs-cTn I (5 ng/L)
identifies low-riskpatients for the composite outcomeof index
myocardial infarction, and myocardial infarction or cardiac
death at 30 dayswith anNPVof 99.6% (95%CI 99.3–99.8%)
[27]. A recent systematic review and meta-analysis demon-
strated that ‘lower cutoffs’ (3–5 ng/L versus 14 ng/L) for a
single baseline hs-cTn Tmeasurement improve sensitivity for
AMI markedly, and can be used as a rule-out test in patients
presentingmore than3 h after symptomonset [28].Therefore,
hs-cTn facilitates earlier exclusion of AMI, contributing to
reduced ED length of stay, and earlier treatment for AMI
resulting in improved outcomes [29]. However, the high
sensitivity of these assays may result in increased numbers of
patientswith elevated hs-cTn levels being admitted for further
assessment.
Causes of hs-cTn elevation and risk
of misinterpretation
There is a misconception that troponin elevation is sec-
ondary only to myocyte injury and necrosis. There are six
mechanisms that have been proposed to explain the release
Fig. 2 Detection range of
different troponin assays. The
green bars represent the normal
turnover range of troponin in
healthy individuals. With the
onset of myocardial infarction, a
slight rise in cardiac troponin
can be seen that represents
either ischemia-induced release
of cytosolic troponin or micro-
necrosis (orange-bars).
Between 2 and 6 h, a steep
increase in levels of cardiac
troponin can be seen that
represents extensive myocardial
necrosis (red-bars). Only this
major increase of cardiac
troponin can be detected by first
to fourth generation troponin
assays. hs-cTn (5th generation
troponin assay) can also detect
lower levels of troponin
including ischemia/micro-
necrosis and even the normal
turnover
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of troponin into the bloodstream: normal cell turnover,
myocyte necrosis, apoptosis or programmed cell death,
proteolytic fragmentation, increased cell membrane per-
meability and membranous blebs.
Whether or not cTn is detectable, or even elevated, is
therefore dependent on the balance of a host of interde-
pendent factors, including the sensitivity of the test. Fur-
thermore, there are potentially other, as yet not described
mechanisms involved in the release of cTn. For example, it
is still unknown why cTn is elevated in certain extra-car-
diac disease processes such as sepsis. Whether ischemia
causes elevated cTn in the absence of myocyte necrosis
remains controversial [30]. Some animal and human
studies demonstrate an association between reversible
ischemia (no evidence of MI) and cTn elevation [31],
whereas others fail to do so [32]. Increased myocardial
strain is also considered to be associated with cTn elevation
[33].
There is a risk of misinterpretation of elevated troponin
results. Almost 13% of patients presenting with raised hs-
cTn and chest pain eventually prove not to have ACS [34].
Hs-cTn can be detected in patients with various cardiac and
non-coronary cardiovascular co-morbidities (Fig. 3).
High-sensitivity cardiac troponin elevation
in chronic kidney disease
More sensitive cTn assays also maintain high diagnostic
accuracy in patients with renal dysfunction when assay-
specific higher optimal cutoff levels are used [35].
Currently, there is no consensus on whether diagnostic
criteria for AMI should differ for patients with and
without impaired renal function [36]. The high preva-
lence of persistently elevated more sensitive cTn levels
in patients with chronic kidney disease (CKD) cannot
primarily be explained by reduced renal clearance alone
[36]. The etiology of persistent troponin elevation in
CKD remains incompletely explained and controversial.
The underlying process appears to be multifactorial
related to both increased subclinical cardiac damage
(uremic toxicity, ischemic heart disease, heart failure or
hypertensive heart disease) and decreased renal clear-
ance in this population [37, 38]. The predictive value of
cTn assays is maintained in patients with CKD [39].
Troponin elevation in patients with CKD should thus be
taken seriously, and not merely be discounted as the
result of decreased renal clearance.
Table 1 Diagnostic
characteristics of validated
high-sensitivity cardiac troponin
assays Adapted from Apple
et al. [23]
Assay LoD (ng/L) 99th % (ng/L) % CV at 99th % 10% CV (ng/L)
hs-cTnT (Elecsys) 5 14 8 13
hs-cTnI (Architect) 1.2 16 5.6 3
hs-cTnI (Dimension Vista) 0.5 9 5 3
High-sensitivity cardiac troponin assays (5th generation)
LOD limit of detection, CV coefficient of variation
Fig. 3 High-sensitivity cardiac
troponin as a quantitative
marker. AMI acute myocardial
infarction, CAD coronary artery
disease, CHF congestive heart
failure, HI healthy individual,
LVH left ventricular
hypertrophy, PE pulmonary
embolus, SAB Staphylococcus
aureus bacteraemia. The lower
the level of hs-cTn, the higher
the negative predictive value
(NPV) for the presence of AMI.
The higher the level of hs-cTn,
the higher the positive
predictive value (PPV) for the
presence of AMI. Levels just
above the 99th percentile have a
low PPV for AM
150 Intern Emerg Med (2017) 12:147–155
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Use of high-sensitivity cardiac troponin in clinical
practice
Acute versus chronic elevation of troponin rise
Both the European Society of Cardiology (ESC) guidelines
on the definition of AMI and suspected ACS endorse the use
of hs-cTn assays [11, 40]. The obvious clinical advantage of
hs-cTn assays is the shorter time interval to the second
measurement of hs-cTn [24]. According to the current
guidelines, a 3 h rule out protocol can now be used [11, 41].
To maintain a high specificity, it is important to distin-
guish acute from chronic hs-cTn elevation. Acute causes of
hs-cTn elevation are associated with a corresponding sig-
nificant rise or fall of hs-cTn. Acute cardiomyocyte injury
causes a steep release of troponins, such as in AMI, shock,
myocarditis, pulmonary embolus, Tako-tsubo (stress-in-
duced) cardiomyopathy. Chronic, stable elevations of hs-
cTn at or above the 99th percentile without a significant
rise or fall are common in patients with structural heart
disease [11]. In these cases, increased ventricular wall
tension is thought to cause direct myofibrillar filament
damage and an increase in programmed cell death, both of
which contribute to hs-cTn release [42]. This has been
observed in patients with left ventricular hypertrophy,
valvular heart disease, stable congestive heart failure,
pulmonary hypertension, stable angina or other forms of
clinically stable cardiomyopathy. Table 2 outlines some
common clinical causes of cTn elevation. Figure 3 depicts
a quantitative approach to hs-cTnT elevation.
High-sensitivity cardiac troponin kinetics with serial
testing
To differentiate acute from chronic troponin elevation and
to maintain a high specificity, clinical evaluation (pre-test
probability) and serial testing of hs-cTn are warranted.
Various rule-in and rule-out algorithms have been proposed
using different time points and cutoff values, including the
question whether absolute or relative hs-cTn changes
Table 2 Other causes of
troponin elevation not
secondary to acute myocardial
infarction (AMI)
Oxygen demand mismatch (in the absence of AMI)
Tachy-/brady-arrhythmias
Hypertensive crisis
Anemia
Hypovolemia or hypotension
Aortic dissection or aortic valve disease
Hypertrophic cardiomyopathy
Strenuous exercise
Direct myocardial damage
Cardiac contusion
Cardiac procedures: cardioversion, pacing, ablation, endomyocardial biopsy
Cardiac infiltrative disorders, e.g., amyloidosis, haemochromatosis, sarcoidosis, sclerodermia
Chemotherapy, e.g., adriamycin, 5-fluorouracil, trastuzumab
Myocarditis or pericarditis
Cardiac transplantation (immune-mediated reactions)
Myocardial strain
Severe congestive heart failure: acute and chronic
Pulmonary embolism
Pulmonary hypertension or COPD
Accumulation of troponin in plasma
Acute/chronic renal dysfunction
Systemic processes
Sepsis
Systemic inflammatory processes
Burns, if affecting[30% of body surface area
Hypothyroidism
Snake venoms
Neurological disorders
Intracerebral hemorrhage or stroke
Seizures
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should be used. The use of any of these change criteria
increases specificity (at the price of slightly decreased
sensitivity) [43]. Despite the excellent performance of hs-
cTn assays in the distinction of patients with AMI from
patients with non-coronary artery cardiac diseases (such as
hypertensive urgency/emergency, acute heart failure, and
cardiac dysrhythmia), evidence for serial testing to improve
specificity for type 1 myocardial infarction (ischemia from
a primary coronary event) versus type 2 myocardial
infarction (secondary to ischemia from a supply-and-de-
mand mismatch) is limited. Most studies that have evalu-
ated whether specificity can be increased by serial troponin
testing have included type 1 and type 2 MI combined [44].
So far, the only study to evaluate the utility of serial testing
to distinguish the more common type 2 from type 1
demonstrates no added advantage of serial testing of con-
ventional troponin I [45]. In summary, while serial hs-cTn
excellently distinguishes between acute and chronic
myocardial injury, it remains uncertain whether it also
helps in the distinction between type 1 and type 2
myocardial infarction.
Optimal cutoffs for (absolute and relative) changes and
the earliest time points of the second hs-cTn measurement
will have to be determined for each assay and clinical
background (pre-test probability, rule-in vs. rule-out of
AMI, special patient populations such as the elderly,
patients with severe renal dysfunction, diabetic patients)
separately and are the subject of current research.
Rule-in and rule-out algorithms for AMI
Figure 4 illustrates two algorithms (3- and 1-h) for rapid
early rule-in and rule-out of acute myocardial infarction
with hs-cTn assays based on current guidelines [40]. The
latest guidelines recommend using the 3-h algorithm
(Fig. 4). In cases of high pre-test probability for NSTEMI
and if chest pain onset [3 h, a 1-h algorithm has been
recommended when hs-cTn assays with a ‘validated
algorithm’ are available (Elecsys, Architect, Dimension
Vista). Assay-specific cutoff values are now available
making use of the continuous, quantitative information of
hs-cTn assays and the concept that the probability of
myocardial infarction increases with increasing hs-cTn
values. Additional blood sampling after 3 h in patients
with strong clinical suspicion of AMI but no significant
rise or fall of hs-cTn may nevertheless still be warranted:
patients with AMI whose hs-cTn is serially measured
around its peak may, e.g., not show any ‘‘significant’’
change. Any hs-cTn algorithm should always be used in
conjunction with clinical assessment of pre-test likelihood
of coronary artery disease, chest pain history and a
12-lead ECG.
Fig. 4 Algorithm for rapid early rule-in and rule-out of acute
myocardial infarction with high-sensitivity cardiac troponin assays,
adapted from [40]. It is generally recommended to use the 3-h
algorithm. In cases of high pre-test probability for NSTEMI and if
chest pain onset[3 h, a 1-h algorithm has now been proposed with
assay-specific hs-cTn cutoff levels. Any algorithm should always be
used in conjunction with clinical assessment and 12-lead ECG.
Repeat blood sampling may be deemed necessary in cases of ongoing
or recurrent chest pain. GRACE ‘‘Global Registry of Acute Coronary
Events score’’, hs-cTn high-sensitivity cardiac troponin, ULN upper
limit of normal, 99th percentile of healthy controls, D change is
dependent on assay, DD differential diagnosis
152 Intern Emerg Med (2017) 12:147–155
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Gender-specific troponin thresholds
Due to a more atypical presentation, women remain a
challenging group with regard to the diagnosis of
myocardial infarction. Studies regarding gender-specific
lower thresholds for women for the diagnosis of acute
myocardial infarction have not shown consistent results:
Shah et al. proposed that women-specific lower diagnostic
thresholds for hs-cTn may double the diagnosis of
myocardial infarction in women, and identify those at high
risk of re-infarction and death [46]. On the other hand, in a
larger recent study by Gime´nez et al., gender-specific tro-
ponin thresholds have not improved diagnostic accuracy,
and it has been proposed that the 99th percentile should
remain the standard of care for both genders [47].
Outlook
Accelerated diagnostic protocols using hs-cTn assays have
now been widely proposed [48], endorsed by current
guidelines [40], and are being adopted in clinical practice
in many countries with the exception of the United States
where hc-cTn assays are still not available. Whereas ESC
guidelines currently propose rapid algorithms for AMI
(0 h/3 h or 0 h/1 h) using hs-cTn assays based on large
validation cohorts, the AHA/ACC guidelines still recom-
mend using conventional troponin assays and the longer
6 h troponin serial measurement [49].
More recently, several studies have tested lower cutoffs
for hs-cTn for ruling out AMI [46, 48, 50]. Lower
thresholds of hs-cTn I have better sensitivity than current
standard thresholds [50]. The use of lower thresholds than
the 99th percentile and very low thresholds below the limit
of detection [50] has a very high NPV for AMI, and might
be helpful in the early discharge of patients.
Conclusion
Cardiac biomarkers for diagnosis of AMI have become
more and more sensitive in recent decades. The currently
used hs-cTn assays are highly valuable for rule-in and rule-
out of AMI. International guidelines have been published
for appropriate use of hs-cTn. Acute changes in hs-cTn
complement the quantitative information provided by hs-
cTn, and help in the differential diagnosis of diseases with
chronic, stable troponin elevations vs. diseases with acute
troponin elevations and acute cardiac damage. Serial test-
ing of hs-cTn does not differentiate Type 1 from Type 2
myocardial infarction and, hence, integrating the results of
hs-cTn measurements with robust clinical assessment
remains the optimal approach.
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